KarMMA-3: Trial of Ide-Cel in Patients with Triple Class Exposed R/R MM

Experts discuss the recent data presented at ASH 2023 from the KarMMA-3 trial in which ide-cel vs standard of care was studied in triple class exposed R/R MM patients.

Related Keywords

,Refractory Multiple Myeloma ,Triple Class Exposed ,Multiple Myeloma ,Relapsed Refractory Multiple Myeloma ,Relapsed Refractory Mm ,Mash 2023 ,Rr Mm ,Bcma Targeted Car T ,Car T ,Karmma 3 ,Ide Cel ,